13F filer · CIK 2081668
Royalty Pharma Sub-Manager, LLC
New York, NY · filing since Q4 2025 · last filing Aug 21, 2026
Reported value
$241.9M
+$69.2M vs prior
Positions
4
New / sold out
1 / 1
Added / reduced
0 / 0
Turnover
17.7%
buys $54.1M · sells $36.6M
Top-10 weight
100.0%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | KAILERA THERAPEUTICS | +2,455,357 | – | +$54.1M |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | BIOCRYST PHARMACEUTICALS INC | -3,846,154 | -100.0% | $-36.6M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | CYTOKINETICS, INCCOM | 980,392 | $83.5M | 34.52% |
| 2 | ZENAS BIOPHARMA, INC.COM | 2,388,150 | $60.6M | 25.05% |
| 3 | KAILERA THERAPEUTICSCOM | 2,455,357 | $54.1M | 22.36% |
| 4 | BIOHAVEN LTDCOM | 2,936,507 | $43.7M | 18.06% |